LYVE1 and melanoma: The reduction of hepatic metastatic foci of B16F10 luc2 and WT31 melanoma in Lyve-1-KO as compared to Ctrl was confirmed by a significant reduction of the total macroscopic and microscopic tumor area in Lyve-1-KO with B16F10 luc2 or WT31 metastases after spleen injection (Additional file 1: Figure S3C, D).